Stock Market & Financial Investment News

News For ABT;ABBV From The Last 14 Days Check below for free stories on ABT;ABBV the last two weeks. Sign up for a free trial to see the rest of the stories you've been missing. June 18, 2013 07:28 EDT ABT Wells Faro to host a conference Subscribe for More Information June 17, 2013 08:17 EDT ABBV AbbVie announces preliminary results in Phase 1 study of ABT-199 Subscribe for More Information June 14, 2013 12:23 EDT ABT Abbott announces new $3B share repurchase plan Subscribe for More Information 12:23 EDT ABT Abbott announces new $3B share repurchase plan June 13, 2013 11:02 EDT ABT Leerink's major pharma analyst holds an analyst/Industry conference call Subscribe for More Information 05:14 EDT ABBV AbbVie presents first study of MTX when used with Humira for RA treatment AbbVie announced the results from the CONCERTO trial, the first randomized, controlled trial assessing different predefined doses of methotrexate, or MTX, in combination with Humira for the treatment of moderate to severe rheumatoid arthritis, or RA. CONCERTO shows that at week 26 of treatment, a statistically significant increasing trend was observed in the proportion of patients achieving low disease activity with an increasing dose of MTX when used with open-label Humira. Results were presented at the European League Against Rheumatism 2013 Congress in Madrid, Spain. The primary objective of CONCERTO was to determine a dose-response pattern of MTX in combination with Humira in MTX and biologic-naive patients with active moderate to severe RA for less than 1 year. Patients were randomized into four treatment arms, receiving 40 mg of open-label Humira every other week in combination with weekly oral MTX at 2.5 mg, 5 mg, 10 mg or 20 mg. June 11, 2013 09:33 EDT ABT Abbott begins Absorb BVS clinical trial in Japan Subscribe for More Information June 10, 2013 07:40 EDT ABBV Leerink's biotech analyst holds analyst/industry conference call on ASCO Subscribe for More Information June 6, 2013 08:03 EDT ABT Abbott shares compelling, says Wells Fargo Subscribe for More Information Sign up for a free trial to see the rest of the stories you've been missing.